Article

Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer Metastasis

2026-03-28

Abstract excerpt

TP53 mutations occur in 80-90% of triple-negative breast cancers (TNBCs) and drive genomic instability and metastatic progression. Poly (ADP-ribose) polymerase (PARP) is critical for DNA repair and replication fork stability. How oncogenic signaling influences PARP function to sustain proliferation during replication stress remains unclear. Mutant p53 (mtp53) R273H associates tightly with chromatin, forms complexe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2856371e-899e-52d5-b87c-fddc6fdd224e
DOI: 10.64898/2026.03.26.713220

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer MetastasisDOI 10.64898/2026.03.26.713220Read

Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast CancerSemantic proximity Read

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.Semantic proximity Read

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatmentSemantic proximity Read

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.Semantic proximity Read

Therapeutic Targeting of DNA Damage Response Pathways in TP53 - and ATM -Mutated TumorsSemantic proximity Read

Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancerSemantic proximity Read

Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4Semantic proximity Read

Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and CisplatinSemantic proximity Read

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistanceSemantic proximity Read

Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast CancerSemantic proximity Read

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsSemantic proximity Read

A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant CancersSemantic proximity Read